Lutetium-177 oxodotreotide (Curium Pharma)

N/A

Report date: 2025/11/27 17:57:23

NME

Base Information

Drug NameLutetium-177 oxodotreotide (Curium Pharma)

Drug Alias NameLu-177 DOTATATE (Curium Pharma)Lutetium Lu 177 Dotatate injection (Curium Pharma)

ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)Diagnostic agent (In vivo)Radiation-emitting products > Radioactive diagnostic agent +[5]

Mechanisms of ActionIonising radiation emittersSomatostatin receptor 2 binders

TargetsSomatostatin receptor 2

Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusIND

Highest Status in ChinaN/A

Originator CompaniesCurium Pharma

China Registration ClassN/A

Develop Information

Active CompaniesCurium Pharma

Inactive CompaniesN/A

Active IndicationsPancreatic neuroendocrine tumors (pNET)

Inactive IndicationsN/A

Other Information

ATC CodeN/A